Related Experiment Video

Updated: Mar 22, 2026

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes
10:33

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

11.3K

Targeting PRAS40 for multiple diseases

Zhao Zhong Chong1

  • 1Department of Anesthesiology, University of Illinois at Chicago, Chicago, IL, USA; Institute of Materia Medica, Shandong Academy of Medical Sciences, Jinan, China.

Drug Discovery Today
|April 18, 2016
PubMed

Insights

Proline-rich Akt substrate 40kDa (PRAS40) regulates mTORC1 signaling. Its phosphorylation by Akt and mTORC1 activates mTORC1, impacting cell death and diseases like cancer and diabetes.

Area of Science:

  • Molecular Biology
  • Cell Signaling
  • Biochemistry

Background:

  • Proline-rich Akt substrate 40kDa (PRAS40) is a key regulator linking protein kinase B (Akt) and the mammalian target of rapamycin complex 1 (mTORC1) signaling pathways.
  • PRAS40 functions as a negative regulator of mTORC1, inhibiting mTOR's interaction with its substrates.
  • Phosphorylation of PRAS40 by Akt or mTORC1 leads to its dissociation from mTORC1, thereby enhancing mTOR activity.

Purpose of the Study:

  • To elucidate the regulatory role of PRAS40 in the Akt/mTORC1 signaling axis.
  • To investigate the impact of PRAS40 phosphorylation on mTORC1 activity and cellular processes.
  • To highlight the therapeutic potential of targeting PRAS40 in disease contexts.

Main Methods:

  • Investigated protein-protein interactions between PRAS40, Akt, and mTORC1.
  • Analyzed the effects of PRAS40 phosphorylation on mTORC1 complex formation and activity.
  • Utilized cell-based assays to assess the role of PRAS40 in programmed cell death and disease-related pathways.

Main Results:

  • Demonstrated that PRAS40 acts as a crucial intermediary in Akt-mTORC1 signaling.
  • Confirmed that phosphorylation of PRAS40 by Akt and mTORC1 promotes mTORC1 activation through dissociation.
  • Established a link between PRAS40/mTORC1 signaling and programmed cell death.

Conclusions:

  • PRAS40 phosphorylation is a critical mechanism for mTORC1 activation.
  • The PRAS40-mTORC1 axis is implicated in major diseases including diabetes mellitus, cardiovascular diseases, cancer, and neurological disorders.
  • Targeting PRAS40 presents a promising therapeutic avenue for these conditions.

More Related Videos

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

1.1K
Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies09:08

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies

Published on: June 2, 2021

2.2K

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
75
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
65
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
11.2K